WM · Q3 2025 Earnings

Bullish

Waste Management

Reported October 27, 2025

30-second summary

Revenue grew 14.9% YoY to $6.44B with the legacy business clearing a 32% operating EBITDA margin — a structural milestone management said "meaningfully surpassed" their longstanding 30% ambition. The FY EBITDA margin ceiling was raised 30bps to 30.2%, FCF and EBITDA dollar guides were reaffirmed, and management front-ran 2026 with an "approaching $3.8B" FCF tease. The quieter signal: FY revenue was narrowed from a $25.275–25.475B range to a $25.275B point — the low end, a $100M midpoint cut framed as a confirmation.

Headline numbers

EPS

Q3 FY2025

$1.98

Revenue

Q3 FY2025

$6.44B

+14.9% YoY

Free cash flow

Q3 FY2025

$0.82B

Operating margin

Q3 FY2025

15.3%

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$6.44B	+14.9%	$6.43B	+0.2%
EPS	$1.98	—	$1.92	+3.1%
Operating margin	15.3%	—	17.9%	-260bps
Free cash flow	$0.82B	—	$0.82B	+0.4%

Guidance

FY2025 revenue guidance narrowed to the low end while EBITDA margin guidance ceiling raised; core EBITDA and FCF reaffirmed.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Revenue	FY2025	$25.275 billion to $25.475 billion	$25.275 billion	-$0.2 billion (narrowed to low end of prior range)	Lowered
Adjusted Operating EBITDA Margin	FY2025	29.6% to 29.9%	29.6% to 30.2%	+0.3 percentage points at high end (30.2% vs prior 29.9%)	Raised

Reaffirmed unchanged this quarter: Adjusted Operating EBITDA ($7.475 billion to $7.625 billion), Free Cash Flow ($2.8 billion to $2.9 billion)

Segment KPIs

Q3 FY2025

Segment	Q3 FY2025	YoY
Collection and Disposal	$5.321B	+4.6%
Recycling Processing and Sales	$0.372B	-13.9%
WM Renewable Energy	$0.115B	+32.2%
WM Legacy Business Adjusted Operating EBITDA Growth	8.7%	—

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Collection and Disposal Adjusted Operating EBITDA Margin	38.4%
Collection and Disposal Core Price	6.0%
Collection and Disposal Yield	3.8%
Collection and Disposal Volume Growth	0.2%
Adjusted Operating EBITDA Margin - Total Company	30.6%
Operating Cash Flow YoY Growth (9M 2025)	12.0%
Free Cash Flow YoY Growth (9M 2025)	13.5%

Management tone

Narrative arc: Q2 "approaching historical best" → Q3 "harvest phase begins, 2026 is the payoff year."

Investment cycle declared over; harvest framing now explicit. Last quarter management said tech and sustainability spend was structurally lowering the cost base; this quarter they drew the line. The verbatim anchor: "we have moved from peak investment levels in sustainability growth projects, landfill infrastructure, and our fleet into a period where we will harvest strong returns on these investments." The Q2 message was "the investments are working." The Q3 message is "the investments are done." That shift is what makes the "approaching $3.8B" 2026 FCF figure credible — it's a capex normalization story, not just an EBITDA story.

Legacy 30% margin target retired, replaced with a new baseline. In Q2 management said the consolidated business was "quickly approaching historical best." This quarter they declared it cleared: "WM's legacy business achieved operating EBITDA margin of 32% in the quarter, meaningfully surpassing our longstanding ambition of sustained operating EBITDA margins above 30%." The word that matters is "meaningfully." The bar is reset; the next conversation is what target replaces 30%.

Healthcare Solutions language shifted from "needle mover delivering" to "synergy proof points landing, revenue lagging." Q2 framing was momentum. Q3 framing is more textured — cross-sell wins are validated (one customer added $5M annual spend; 7,000+ small/medium conversions split 50/50 between WM and legacy Stericycle bases per Q&A) and segment margin is improving sequentially, but management acknowledged revenue growth is at "a more measured pace than initial projections" and ERP stabilization now slips to well into 2026. The structural thesis is intact; the timing tail is longer.

Industrial volume inflection is the new "look at this" data point. Q2 management was selling the durability of MSW and landfill volumes. This quarter the punchline is "industrial up 1.2%, our first positive quarter since 2022" — about half driven by healthcare customer internalization, half by genuine cyclical recovery in roll-off. This is the first cyclical bull signal management has volunteered in several quarters and supports the read that 2026 is a top-line story as well as a cash story.

Recurring themes management leaned on this quarter:

Investment harvest phase entering 2026 with strong FCF guidance ($3.8B)Record margin expansion: 32% legacy business EBITDA margin surpassing 30% targetHealthcare solutions synergy capture exceeding expectations with strong cross-sell momentumOperational efficiency gains from fleet technology and workforce investments yielding structural cost reductionsVolume recovery across all business segments including first positive industrial quarter since 2022Disciplined pricing strategy maintaining price-to-cost spread with 6% core price and strong customer retention

Risks management surfaced:

Recycled commodity prices declined nearly 35% year-over-yearHealthcare solutions revenue growth at more measured pace than initial projectionsAlternative fuel tax credit exploration creating 30 basis point headwindForward-looking statements subject to risks and uncertainties that could cause actual results to differ materiallyLeverage ratio requires path to 2.5-3x target by mid-2026

Q&A highlights

Tyler Brownwood · Raymond James

Asked about year-to-date wildfire cleanup revenue impact, charges related to Natura plastics plant idling, and landfill closure impairment; also requested guidance on free cash flow drivers for 2026 and sustainability EBITDA targets.

Management disclosed $115M in wildfire-related revenues year-to-date with higher flow-through margins (~45%+ for landfill/special events); Natura plant closure driven by low virgin plastic prices and delayed minimum content legislation, not technology issues; Northeast hazardous waste landfill expansion pursuit abandoned due to regulatory issues, triggering impairment and accelerated closure cost accruals. Free cash flow improvement of ~$26B expected from sustainability investment wind-down, fleet capex normalization (~1,500 trucks vs. 6,000 over 3 years), and healthcare solutions synergies; confirmed sustainability EBITDA tracking toward 2025 target with step-up expected in Q4.

$115M year-to-date wildfire revenue45%+ flow-through margin on landfill/special event volumes$145M EBITDA growth in solid waste Q3 without wildfire impact~$26B free cash flow guidance for 2026

Noah Kay · Oppenheimer

Requested detail on MSW volume strength, industrial volume inflection drivers, and factors determining margin guidance range achievement.

Management attributed MSW volume strength to network robustness rather than single geographic or service factor, with 6.7% yield on MSW. Industrial volume improvement (+first positive quarter in 3 years) driven 50% by healthcare solutions customer internalization and 50% by genuine business uptick from temp roll-off recovery and permanent customer volume growth. Margin confidence stems from 32% collection & disposal margins reflecting retention benefits, fleet investment, price-cost spread improvement, and favorable mix. Expect Q4 margin performance at midpoint to upper end of guidance due to strong RIN sales (~100% margin accretive) and continued pricing strength.

MSW yield 6.7%Industrial volume first positive quarter in 3 years50% of industrial improvement from healthcare internalization32% collection & disposal margin in Q3

Trevor Romeo · William Blair

Asked about healthcare solutions pricing increase deferrals, customer pushback specifics, long-term pricing power, and confidence in achieving mid-single-digit revenue growth; also requested price-cost spread outlook for 2026+.

Management described pricing increase deferrals as proactive customer-first decisions rather than reactive to pushback, acknowledging ERP implementation frustration and issuing one-time credits to clear aged AR (1/3 cleared in 3 months). Emphasized healthcare business strategic strength with strong secular trends (aging population), best-in-class market position, and renewed $200M in contracts at low double-digit price increases. ERP stabilization expected through Q1 2026 with 'when' not 'if' for resolution. Long-term 5-6% revenue growth remains achievable post-stabilization. Core price yielding 6% vs. ~2.93% CPI with continued pricing discipline across all waste streams; driver turnover at all-time low supporting cost absorption.

$200M in renewals at low double-digit PIs1/3 of aged healthcare AR cleared in 3 monthsERP stabilization target: end of Q1 20266% core solid waste price vs. 2.93% CPI

Tony Kaplan · Morgan Stanley

Asked about yield trends (noting industrial yield at lowest since COVID) and 2026 customer conversations; also inquired about M&A pipeline and valuations.

Management confirmed industrial yield of 2.3% reflects mix of healthcare customer internalization (lower-priced temporary work, though still profitable) and uptick in permanent customer volumes. Core price for industrial 5.7% remains strong with 38.4% overall collection & disposal margins. Solid waste M&A year-to-date ~$450M with potential for ~$500M by year-end; 2026 expectations $100-200M in traditional solid waste acquisitions. Emphasized capacity for larger strategic opportunities and likelihood of substantial share repurchases in 2026 from $3.8B+ free cash flow generation.

Industrial yield 2.3% (lowest since COVID)Industrial core price 5.7%Collection & disposal margin 38.4%YTD M&A $450M, potential $500M by year-end

Robert Heimer · Melius Research

Sought clarification on healthcare solutions cross-selling activities and progress; asked about customer acquisition and win-back potential from cross-sell integration.

Management clarified that industrial volume improvements include internalization of legacy Stericycle volumes redirected to WM from competitors, constituting true cross-sell. Cross-sell success spans all channels: 7,000+ small/medium customer conversions (50-50 WM/Stericycle split) and large hospital network wins. Specific example: one customer increased annual spend by $5M across multi-state network. Win-back potential for churned customers remains high due to network scale advantage; competitors cannot replace full Stericycle network capability, creating incentive for customers to return. Service quality strong (superior on-time delivery vs. legacy WM, better net promoter score).

7,000+ cross-sell completions to small/medium customers50-50 split between WM and Stericycle original customer basesOne customer $5M annual spend increase across multi-state networkMultiple customers increased spend in seven-figure annual revenue range

Answers to last quarter's watch list

Q3 FY2025 consolidated EBITDA margin vs. the 31% Q3 FY2024 prior peak. Consolidated adj. operating EBITDA margin came in at 30.6% — below the 31% Q3 FY2024 print on the headline, but the legacy business cleared 32% while still absorbing Healthcare Solutions dilution. Management explicitly framed this as proof the structural thesis is intact. The FY margin ceiling raise to 30.2% (from 29.9%) corroborates. Status: Resolved positively.

Stericycle synergy exit-rate update toward $150M. The press release and Q&A summary did not surface a quantified updated exit-rate disclosure for synergies this quarter. Cross-sell metrics (7,000+ conversions, multiple seven-figure customer wins, +$5M from one customer) were offered as qualitative proof, and segment margin improved to 17.5%, but a hard run-rate number was not put on the page. Status: Continue monitoring.

Residential volume loss moderation toward -2.7%. C&D volume turned positive at +0.2% overall and industrial flipped to +1.2% for the first time since 2022, but a clean residential volume disclosure was not surfaced in this print. Status: Continue monitoring.

Recycled commodity prices and recycling EBITDA decoupling. Commodity prices fell ~35% YoY (vs. –15% in Q2), and recycling revenue dropped 13.9%. Management noted recycling segment operating EBITDA grew 18% despite the commodity hit — automation investments more than offset price. The decoupling thesis got reinforced under a harder test. Status: Resolved positively.

FY FCF print relative to the $2.8–2.9B range. 9M FCF reached $2.11B (+13.5% YoY), implying Q4 needs ~$0.7–0.8B to land inside the reaffirmed $2.8–2.9B FY range. Management reaffirmed FCF guidance unchanged and pointed to Q4 RIN sales as a margin/cash tailwind, but the FY guide is not de-risked on a 9M basis — Q4 still has to deliver. Status: Continue monitoring.

What to watch into next quarter

The Q4 print vs. the new FY revenue point of $25.275B. With 9M revenue tracking and Q4 the swing, any further softness puts the explicitly-named point at risk — and would force management to either undershoot a quantified guide for the first time this cycle or pre-announce. Watch whether RIN-driven Q4 margin upside masks any volume soft spots.

2026 formal guidance: does the "approaching $3.8B" FCF tease anchor as a midpoint or a ceiling? A $3.7–3.9B range validates the harvest narrative; anything starting with a 3.5 would suggest the tease was aspirational and force a tone reset.

Healthcare Solutions revenue growth trajectory post-ERP stabilization. Management has now twice acknowledged revenue is at a "more measured pace than initial projections." Watch whether the segment can show sequential revenue acceleration in Q4 or whether the timing tail extends further into 2026.

Quantified Stericycle synergy exit-rate. Q2 guided to ~$150M exit-rate by year-end 2025. Q3 went qualitative. If Q4 does not put a number on the page, the bull-case 2026 EBITDA build loses an important anchor.

Industrial volume durability. +1.2% was the first positive print since 2022 and management volunteered it. If Q4 sustains positive industrial growth ex-healthcare-internalization, the cyclical recovery thesis gets real; if it slips back to flat or negative, the +1.2% gets re-classified as a mix artifact.

Sources

WM Q3 FY2025 Press Release (Form 8-K Exhibit 99.1), SEC filing dated October 27, 2025 — https://www.sec.gov/Archives/edgar/data/823768/000110465925102615/tm2529298d1_ex99-1.htm
WM Q2 FY2025 Tapebrief (prior-quarter context, internal).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.